FGAM
VRTX icon

Financial Gravity Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Financial Gravity Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.79K Buy
+4
New +$1.86K ﹤0.01% 722
2024
Q2 		– Sell
-39
Closed -$16.3K – 2425
2024
Q1 		$16.3K Buy
39
+16
+70% +$6.76K ﹤0.01% 594
2023
Q4 		$9.51K Buy
23
+12
+109% +$4.43K ﹤0.01% 793
2023
Q3 		$4.38K Sell
11
-341
-97% -$119K ﹤0.01% 638
2023
Q2 		$4.57K Buy
352
+37
+12% +$12.5K 0.01% 496
2023
Q1 		$4.61K Buy
315
+26
+9% +$7.8K 0.14% 163
2022
Q4 		$4.03K Sell
289
-7,831
-96% -$2.39M 0.02% 434
2022
Q3 		$4.45K Sell
8,120
-340
-4% -$97.8K 0.15% 139
2022
Q2 		$4.6K Buy
8,460
+630
+8% +$169K 0.14% 148
2022
Q1 		$4.83K Buy
7,830
+4,970
+174% +$1.18M 0.14% 151
2021
Q4 		$1.62K Buy
2,860
+2,853
+40,757% +$555K 0.04% 348
2021
Q3 		$181K Hold
7
– – 0.09% 206
2021
Q2 		$202K Sell
7
-4
-36% -$837 0.07% 187
2021
Q1 		$2.37K Sell
11
-33
-75% -$7.25K 0.05% 227
2020
Q4 		$10K Buy
+44
New +$10.1K 0.01% 181
2020
Q2 		– Sell
-297
Closed -$70.6K – 898
2020
Q1 		$70.6K Sell
297
-206
-41% -$47.3K 0.22% 50
2019
Q4 		$219K Sell
503
-251
-33% -$50.8K 0.15% 99
2019
Q3 		$128K Sell
754
-167
-18% -$29.5K 0.11% 175
2019
Q2 		$169K Sell
921
-197
-18% -$34.4K 0.14% 165
2019
Q1 		$208K Buy
+1,118
New +$206K 0.17% 131
2018
Q3 		$227K Buy
1,334
+214
+19% +$38.1K 0.24% 95
2018
Q2 		$196K Sell
1,120
-96
-8% -$14.9K 0.18% 117
2018
Q1 		$182K Buy
+1,216
New +$199K 0.19% 107

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Financial Gravity Asset Management's VRTX Position: Q1 2026 in Review

Financial Gravity Asset Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q1 2026: 4 shares worth $1.79K. The stake represents ﹤0.01% of the portfolio and ranks #722 among its holdings. This is a return to the name: Financial Gravity Asset Management previously reported a position in VRTX as recently as Q1 2024.

Financial Gravity Asset Management first reported a position in VRTX in Q1 2018 and has held it in 23 quarters since. The position peaked at $227K in Q3 2018. 1,695 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Financial Gravity Asset Management held 4 shares of Vertex Pharmaceuticals worth $1.79K as of Q1 2026.
  • Vertex Pharmaceuticals was a new Financial Gravity Asset Management position in Q1 2026.
  • Vertex Pharmaceuticals made up ﹤0.01% of Financial Gravity Asset Management's portfolio in Q1 2026, its #722 holding.
  • Financial Gravity Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2018 and has held it in 23 quarters since.
  • Financial Gravity Asset Management's Vertex Pharmaceuticals position peaked at $227K in Q3 2018.
  • 1,695 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Financial Gravity Asset Management's 13F filing for Q1 2026, filed 8 May 2026.